The growth of Viagra and its effect on the pharmaceutical landscape presents a intricate question for shareholders. While the initial sales statistics were impressive, the patent has expired, leading to a deluge of generic alternatives that are chipping away at profit. Moreover, the sector is facing challenges related to demographic trends and evol